FATHOM RECEIVES STRATEGIC FUNDING FROM CVS HEALTH VENTURES TO BOOST ENTERPRISE-WIDE AUTONOMOUS CODING INITIATIVES
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Should l Buy CVS?
Source: moomoo
- Investment Announcement: Fathom has secured a strategic investment from CVS Health Ventures.
- Focus on Innovation: The funding aims to accelerate enterprise-wide autonomous coding solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to fall
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 97.150
Low
91.00
Averages
96.71
High
105.00
Current: 97.150
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Earnings Season Volatility Hits US Stocks
- Strong Earnings Season: As the earnings season progresses, the S&P 500 reached an intraday record high of 7,501.24 on Thursday, reflecting strong investor confidence in corporate earnings, although it pulled back on Friday due to declines in tech stocks.
- Cisco's Stock Surge: Cisco shares soared 22% in one week following better-than-expected fiscal Q3 results, with a relative strength index (RSI) of 90 indicating the stock is in overbought territory, suggesting a potential short-term pullback risk.
- Zoetis Decline: Zoetis topped the oversold list with a 10% drop in the past week and an RSI of 14.4, as its Q1 earnings fell short of expectations and it lowered full-year EPS and revenue guidance, indicating pet owners are cutting back on vet visits due to price pressures.
- Market Sentiment Fluctuations: Despite strong performances from stocks like Cisco, the overall market experienced volatility due to disappointment over the U.S.-China summit outcomes, prompting investors to watch for potential rebounds in overbought and oversold stocks.
See More
Amazon Launches 30-Minute Ultra-Fast Delivery Service
- Service Expansion: Amazon's ultra-fast delivery service, Amazon Now, is now live in cities like Atlanta, Dallas-Fort Worth, Philadelphia, and Seattle, with plans to reach tens of millions of customers by year-end, significantly enhancing the company's competitive edge in the fast-moving consumer goods market.
- Pricing Structure: Prime members pay a delivery fee of $3.99, while non-members are charged $13.99, with additional fees for orders under $15, a pricing strategy designed to attract more users to join Prime, thereby increasing customer loyalty.
- Logistics Network Optimization: To achieve 30-minute delivery, Amazon has established smaller fulfillment centers close to customers, a strategy that not only improves delivery efficiency but also solidifies Amazon's market position in e-commerce.
- Positive Market Response: Since March 27, Amazon's stock has risen over 30%, reflecting investor confidence in its rapid delivery services, with analysts suggesting this will help Amazon capture a larger share of the $1.7 trillion offline grocery market.
See More
CVS Health's Omnicare Unit Approved for Sale
- Bankruptcy Court Approval: CVS Health's Omnicare unit has received approval from the U.S. Bankruptcy Court for the Northern District of Texas to sell its operations to GenieRx Holdings for $250 million in cash, with the transaction expected to close later this year, marking a significant step in the company's bankruptcy proceedings.
- Transaction Context: This sale follows Omnicare's Chapter 11 bankruptcy filing initiated last September due to a ruling against the company for improper billing practices, which severely impacted its financial health and necessitated a restructuring through asset sales.
- Liability Assumption: The deal includes the assumption of certain payroll and other liabilities, meaning that GenieRx will take on some financial responsibilities, which could influence its future financial performance and operational strategies.
- Market Reaction: While CVS Health's overall financial condition remains weak, the approval of this transaction may provide a short-term influx of capital, aiding the company in making significant strides toward financial recovery in the future.
See More
Key Market Insights: Semiconductor and AI Stocks
- Semiconductor and AI Stock Rebound: After a day of selling, stocks like Micron and Corning are rebounding this morning, indicating ongoing market interest in semiconductor and AI stocks, despite S&P futures declining due to hotter-than-expected April wholesale inflation data.
- Nvidia Price Target Increase: Bank of America raised Nvidia's price target from $300 to $320, reflecting optimism ahead of its upcoming earnings report, while CEO Jensen Huang's attendance at the summit with Trump in China may further boost the stock.
- Qnity Electronics Strong Performance: Following a strong earnings report, Qnity Electronics saw price target increases from Deutsche Bank and BMO Capital to $180 and $200 respectively, showcasing market confidence in AI stocks, particularly amidst a broader market downturn.
- Johnson & Johnson Rating Upgrade: Leerink upgraded Johnson & Johnson to a buy rating with a price target increase from $252 to $265, anticipating sales for its psoriasis drug Icotyde to reach $10.5 billion by 2032, significantly above the consensus estimate of $7.4 billion, highlighting its growth potential.
See More
CVS Health Shares Rise 3% on Analyst Upgrades and Strong Earnings
- Analyst Upgrades: Lisa Gill from JPMorgan raised CVS's price target to $111, a $10 increase from her previous estimate, reflecting confidence in the company's future performance, while Lance Wilkes also increased his target from $94 to $106, further boosting market optimism.
- Strong Earnings Report: CVS reported a 66% year-over-year increase in net income to nearly $3 billion in Q1, demonstrating robust profitability, which positively influenced investor sentiment and highlighted the company's competitive strength in the retail healthcare sector.
- Improved Medical Benefit Ratio: The company successfully reduced its medical benefit ratio by nearly three percentage points, indicating significant progress in cost control and operational efficiency, which will enhance profitability and market appeal.
- Raised Profit Guidance: CVS has also raised its profitability guidance for 2026, reflecting confidence in future growth; combined with its strong market position, this is expected to attract more investor interest and drive stock price appreciation.
See More
CVS Health Stock Hits New High Amid Strong Earnings
- Strong Earnings Report: CVS Health reported first-quarter revenue for 2026 exceeding $100.4 billion, reflecting over a 6% year-over-year increase, which demonstrates robust growth momentum and boosts investor confidence.
- Significant Net Income Growth: The company's net income approached $3 billion, marking a substantial 66% increase from the previous year, indicating CVS's notable progress in cost control and profitability, likely attracting more investor interest.
- Improved Medical Benefit Ratio: CVS's medical benefit ratio (MBR) decreased to 84.6% from 87.3% a year ago, suggesting enhanced predictability in medical claims expenditures, which helps to bolster investor confidence.
- Stock Price Potential: Although CVS's stock has reached a new high of $92.77, its forward price-to-earnings ratio stands at 13, significantly lower than the S&P 500's 22, indicating substantial upside potential, while its 2.9% dividend yield offers investors a stable return.
See More
Earnings Season Volatility Hits US Stocks
- Strong Earnings Season: As the earnings season progresses, the S&P 500 reached an intraday record high of 7,501.24 on Thursday, reflecting strong investor confidence in corporate earnings, although it pulled back on Friday due to declines in tech stocks.
- Cisco's Stock Surge: Cisco shares soared 22% in one week following better-than-expected fiscal Q3 results, with a relative strength index (RSI) of 90 indicating the stock is in overbought territory, suggesting a potential short-term pullback risk.
- Zoetis Decline: Zoetis topped the oversold list with a 10% drop in the past week and an RSI of 14.4, as its Q1 earnings fell short of expectations and it lowered full-year EPS and revenue guidance, indicating pet owners are cutting back on vet visits due to price pressures.
- Market Sentiment Fluctuations: Despite strong performances from stocks like Cisco, the overall market experienced volatility due to disappointment over the U.S.-China summit outcomes, prompting investors to watch for potential rebounds in overbought and oversold stocks.
See More
Amazon Launches 30-Minute Ultra-Fast Delivery Service
- Service Expansion: Amazon's ultra-fast delivery service, Amazon Now, is now live in cities like Atlanta, Dallas-Fort Worth, Philadelphia, and Seattle, with plans to reach tens of millions of customers by year-end, significantly enhancing the company's competitive edge in the fast-moving consumer goods market.
- Pricing Structure: Prime members pay a delivery fee of $3.99, while non-members are charged $13.99, with additional fees for orders under $15, a pricing strategy designed to attract more users to join Prime, thereby increasing customer loyalty.
- Logistics Network Optimization: To achieve 30-minute delivery, Amazon has established smaller fulfillment centers close to customers, a strategy that not only improves delivery efficiency but also solidifies Amazon's market position in e-commerce.
- Positive Market Response: Since March 27, Amazon's stock has risen over 30%, reflecting investor confidence in its rapid delivery services, with analysts suggesting this will help Amazon capture a larger share of the $1.7 trillion offline grocery market.
See More
CVS Health's Omnicare Unit Approved for Sale
- Bankruptcy Court Approval: CVS Health's Omnicare unit has received approval from the U.S. Bankruptcy Court for the Northern District of Texas to sell its operations to GenieRx Holdings for $250 million in cash, with the transaction expected to close later this year, marking a significant step in the company's bankruptcy proceedings.
- Transaction Context: This sale follows Omnicare's Chapter 11 bankruptcy filing initiated last September due to a ruling against the company for improper billing practices, which severely impacted its financial health and necessitated a restructuring through asset sales.
- Liability Assumption: The deal includes the assumption of certain payroll and other liabilities, meaning that GenieRx will take on some financial responsibilities, which could influence its future financial performance and operational strategies.
- Market Reaction: While CVS Health's overall financial condition remains weak, the approval of this transaction may provide a short-term influx of capital, aiding the company in making significant strides toward financial recovery in the future.
See More
Key Market Insights: Semiconductor and AI Stocks
- Semiconductor and AI Stock Rebound: After a day of selling, stocks like Micron and Corning are rebounding this morning, indicating ongoing market interest in semiconductor and AI stocks, despite S&P futures declining due to hotter-than-expected April wholesale inflation data.
- Nvidia Price Target Increase: Bank of America raised Nvidia's price target from $300 to $320, reflecting optimism ahead of its upcoming earnings report, while CEO Jensen Huang's attendance at the summit with Trump in China may further boost the stock.
- Qnity Electronics Strong Performance: Following a strong earnings report, Qnity Electronics saw price target increases from Deutsche Bank and BMO Capital to $180 and $200 respectively, showcasing market confidence in AI stocks, particularly amidst a broader market downturn.
- Johnson & Johnson Rating Upgrade: Leerink upgraded Johnson & Johnson to a buy rating with a price target increase from $252 to $265, anticipating sales for its psoriasis drug Icotyde to reach $10.5 billion by 2032, significantly above the consensus estimate of $7.4 billion, highlighting its growth potential.
See More
CVS Health Shares Rise 3% on Analyst Upgrades and Strong Earnings
- Analyst Upgrades: Lisa Gill from JPMorgan raised CVS's price target to $111, a $10 increase from her previous estimate, reflecting confidence in the company's future performance, while Lance Wilkes also increased his target from $94 to $106, further boosting market optimism.
- Strong Earnings Report: CVS reported a 66% year-over-year increase in net income to nearly $3 billion in Q1, demonstrating robust profitability, which positively influenced investor sentiment and highlighted the company's competitive strength in the retail healthcare sector.
- Improved Medical Benefit Ratio: The company successfully reduced its medical benefit ratio by nearly three percentage points, indicating significant progress in cost control and operational efficiency, which will enhance profitability and market appeal.
- Raised Profit Guidance: CVS has also raised its profitability guidance for 2026, reflecting confidence in future growth; combined with its strong market position, this is expected to attract more investor interest and drive stock price appreciation.
See More
CVS Health Stock Hits New High Amid Strong Earnings
- Strong Earnings Report: CVS Health reported first-quarter revenue for 2026 exceeding $100.4 billion, reflecting over a 6% year-over-year increase, which demonstrates robust growth momentum and boosts investor confidence.
- Significant Net Income Growth: The company's net income approached $3 billion, marking a substantial 66% increase from the previous year, indicating CVS's notable progress in cost control and profitability, likely attracting more investor interest.
- Improved Medical Benefit Ratio: CVS's medical benefit ratio (MBR) decreased to 84.6% from 87.3% a year ago, suggesting enhanced predictability in medical claims expenditures, which helps to bolster investor confidence.
- Stock Price Potential: Although CVS's stock has reached a new high of $92.77, its forward price-to-earnings ratio stands at 13, significantly lower than the S&P 500's 22, indicating substantial upside potential, while its 2.9% dividend yield offers investors a stable return.
See More
